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Mutations of the tumor suppressor PTEN, a phosphatase with
specificity for 3-phosphorylated inositol phospholipids, accom-
pany progression of brain tumors from benign to the most malig-
nant forms. Tumor progression, particularly in aggressive and
malignant tumors, is associated with the induction of angiogene-
sis, a process termed the angiogenic switch. Therefore, we tested
whether PTEN regulates tumor progression by modulating angio-
genesis. U87MG glioma cells stably reconstituted with PTEN cDNA
were tested for growth in a nude mouse orthotopic brain tumor
model. We observed that the reconstitution of wild-type PTEN had
no effect on in vitro proliferation but dramatically decreased tumor
growth in vivo and prolonged survival in mice implanted intracra-
nially with these tumor cells. PTEN reconstitution diminished
phosphorylation of AKT within the PTEN-reconstituted tumor,
induced thrombospondin 1 expression, and suppressed angiogenic
activity. These effects were not observed in tumors reconstituted
with a lipid phosphatase inactive G129E mutant of PTEN, a result
that provides evidence that the lipid phosphatase activity of PTEN
regulates the angiogenic response in vivo. These data provide
evidence that PTEN regulates tumor-induced angiogenesis and the
progression of gliomas to a malignant phenotype via the regula-
tion of phosphoinositide-dependent signals.
The reversible phosphorylation of proteins and lipids is criticalto the control of signal transduction in mammalian cells and
is regulated by kinases and phosphatases (1). The product of the
tumor suppressor gene PTENyMMAC (hereafter termed
PTEN) was identified as a dual specificity phosphatase and has
been shown to dephosphorylate inositol phospholipids (2–9).
The PTEN gene is mutated in 40–50% of high-grade gliomas as
well as prostate, endometrial, breast, lung, and other tumors (2,
3, 10). In addition, PTEN is mutated in several rare autosomal
dominant cancer predisposition syndromes, including Cowden
disease, Lhermitte-Duclos disease, and Bannayan-Zonana syn-
drome (11–14). The phenotype of PTEN-knockout mice reveal
a requirement for this phosphatase in normal development and
confirm its role as a tumor suppressor (15–17).
PTEN is a 55-kDa protein comprising an N-terminal catalytic
domain, identified as a segment with homology to the cytoskel-
etal protein tensin and containing the sequence HC(X)5R, which
is the signature motif of members of the protein tyrosine
phosphatase family, and a C-terminal C2 domain with lipid-
binding and membrane-targeting functions (18). The sequence
of the extreme C terminus of PTEN suggests a function in
binding PDZ domain-containing proteins. PTEN is a dual
specificity phosphatase that displays a pronounced preference
for acidic substrates (5). Importantly, PTEN possesses lipid
phosphatase activity, preferentially dephosphorylating phos-
phoinositides at the D3 position of the inositol ring. It is the only
enzyme known to dephosphorylate the D3 position in inositol
phospholipids, suggesting that PTEN may function as a direct
antagonist of phosphatidylinositol 3-kinase (PI3-kinase) and
phosphatidylinositol 3,4,5-trisphosphate [PtdIns(3,4,5)P3]-
dependent signaling (7, 13). Reconstitution of PTEN in tumor
cells that carry mutations in the PTEN gene have established
that this phosphatase regulates the PI3-kinase-dependent acti-
vation of AKT, a major player in cell survival (6, 14). However,
despite progress in understanding the biochemistry of PTEN,
the role of this phosphatase in tumor progression, as it relates to
its diverse effects on cell growth, angiogenesis, andyor survival,
remains unclear.
Mutations in PTEN accompany progression of brain tumors
from grade IyII to malignant grade III and IV in vivo (19, 20).
Tumor progression is associated with angiogenesis, the formation
of new blood vessels from existing vascular structures, with in-
creases in microvessel density (MVD) and increased invasion of
tumor cells into brain parenchyma (21–23). For tumor growth to
occur, tumor dormancy must be broken, an event termed the
angiogenic switch. During angiogenesis endothelial cells are in-
duced to degrade the basement membrane of existing vessels, break
away, and migrate to the site of the tumor, where they proliferate
to form linear structures that differentiate to form blood vessels.
Factors that control angiogenesis include growth factors, matrix
metalloproteinases, plasminogen activators, thrombospondins, in-
tegrins avb3, avb5, and a5b1, etc. (23–25). The angiogenic switch
involves a shift in the balance of angiogenic stimulators and
angiogenic inhibitors. Stimulators include the growth factors, vas-
cular endothelial growth factor and basic fibroblast growth factor,
and the induction of matrix remodeling via matrix metal-
loproteinases (26). Inhibitors include thrombospondin 1 (TSP-1),
angiostatin, endostatin, tissue inhibitors of metalloproteinases, and
others (24, 27). It has been observed that neovascularization and
PTEN mutations are associated with high-grade gliomas and are
not observed in low-grade glial tumors, leading to the hypothesis
that these two events may be causally linked.
Regulation of PI3-kinase-dependent signals, including activa-
tion of AKT by vascular endothelial growth factor and its
receptors, the protein tyrosine kinases Flt-1 and KDR, have been
implicated in brain tumor angiogenesis (28). Data generated in
the chicken chorioallantoic membrane model suggests that PI3-
kinase-dependent pathways may regulate angiogenesis and vas-
cular endothelial growth factor expression in endothelial cells
(29). Furthermore, correlative studies in prostate tumor speci-
mens have demonstrated that tumors containing PTEN muta-
tions have higher microvessel counts than tumors expressing
wild-type (WT) PTEN (30). However, whether PTEN is causally
linked to induction of angiogenesis by the tumor cell remains
unproven. These and other observations led us to hypothesize
that PTEN may control tumor-induced angiogenesis and con-
tribute to the high mortality associated with malignant brain
tumors.
Materials and Methods
Cell Culture, Constructs, and Reagents. WT PTEN or mutant PTEN
(G129E, R130 M) cDNAs were subcloned into the pBabe-puro
retroviral expression vector. Stable clones of U87MG cells
expressing WT PTEN (WT.E1, WT.C7) or mutant PTEN
(G129E, R130 M) were established under puromycin selection
Abbreviations: PI3-kinase, phosphatidylinositol 3-kinase; PtdIns(3,4,5)P3, phosphatidylino-
sitol 3,4,5-trisphosphate; TSP-1, thrombospondin 1; WT, wild type; MVD, microvessel
density.
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(2 mgyml) (6). Muristirone-induced expression of PTEN in
U87MG cells was performed as described by J. Stolarov (31).
Antibodies were obtained specific for PTEN (6), AKT and
phospho-S473-AKT (New England Biolabs, #9270), TSP-1 (Cal-
biochem, #605230), and anti-BrdUrd mAb clone BU33 (Sigma,
#B9285).
Tumor Implantation. Cells were cultured in fresh medium for 24 h
and harvested, adjusting the cell concentration to 1 3 106 in 10
ml of RPMI medium. Mice, under general anesthesia were placed
into the stereotactic device (model 963, Kopf Instruments,
Tujunga, CA). Stereotactically controlled drill assembly was
used to provide a hole 0.3 mm deep and of 0.8 mm diameter in
cranium at a position 0.5 mm anterior and 1.2 mm lateral to the
bregmal anatomical landmark. Tumor cells (1 3 106) were
introduced slowly through a 10-ml Hamilton syringe at a depth
of 2.5 mm at a rate of 2 mlymin. We then slowly removed the
needle at a rate of 0.5 mmymin. After needle removal we sealed
the hole with bone wax and closed the incision with a wound clip.
In some of the mice, 5 3 106 tumor cells were implanted s.c. into
the right flank to monitor tumor volume and to perform
biochemical and immunohistochemical analysis of tumor tissue.
All animal experiments performed were approved by the Animal
Care Committee at Indiana University School of Medicine.
Biochemical Analysis. Immunoblots were performed on cell lysates
obtained from U87 cells grown in tissue culture or from multiple
cryostat sections of s.c. tumor tissues. A Bradford assay was
performed to determine protein concentration of each lysate.
Equivalent amounts of protein were resolved by SDSyPAGE and
transferred to nitrocellulose. Membranes were probed with
antisera specific for PTEN, AKT, phospho-S473-AKT, or TSP-1.
The RNase protection assay was performed by using a RPA III
kit from (Ambion) according to the manufacturer’s specifica-
tions. Briefly, 20 mg of total RNA was precipitated and resus-
pended in 10 ml of hybridization buffer containing the radioac-
tive probe. The RNA then was heated to 95°C for 10 min and
hybridized for 16 h at 42°C. A total of 150 ml of this mixture was
treated with 1:100 dilution of RNase in RNase buffer for 30 min.
RNase was inactivated, and RNA was reprecipitated and re-
solved on 5% acrylamide gel. RNA probes were synthesized by
using MAXI SCRIPT using PCR templates and T7 polymerase. The
glyceraldehyde-3-phosphate dehydrogenase probe was provided
in the kit, and TSP-1 probe represents a 590-nt sequence in the
39 untranslated region of TSP-1 sequence. All probes were
sequenced.
Immunohistochemical Analysis. MVD was determined for each s.c.
and brain tumors by CD31 staining, and a proliferative index was
determined by using anti-BrdUrd mAb staining performed on
cryostat sections (7 mm), fixed in acetone, blocked in 1% goat
serum, and stained with anti-CD31 antibody (PharMingen,
#01951D). Antibody staining was visualized with peroxidase-
conjugated anti-mouse and counterstained with hematoxylin. A
negative control was performed on each tumor tissue stained
with mouse IgG. Two sections from each tumor were scanned
under low-power magnification (340) to identify areas of highest
CD31-positive vessel density (32), followed by digitization of
three fields from this area. For in vivo BrdUrd labeling, mice
received 100 ml of BrdUrd in PBS (10 mM) injected into the tail
vein 1 h before tumor harvesting. The digitized images repre-
senting one 320 field were counted for the number of CD31-
positive vascular elements and number of BrdUrd-positive cellsy
field. The number of cells positive for BrdUrd staining ranged
between 5% and 8% of total number of tumor cells. Data were
collected from two independent observers without knowledge of
which tumors were viewed. The average number of microvessels
or cells positive for BrdUrd staining per digitized field was
determined for five tumors per experimental group and analyzed
by Student’s t test.
Results
Effect of PTEN Reconstitution on in Vitro Growth of Tumor. To
determine whether PTEN exerts control over angiogenesis and
the growth of glial tumors, we developed an orthotopic brain
tumor model in which PTEN-deficient tumor cells were genet-
ically manipulated in vitro and then stereotactically injected into
the skin or frontal cerebral cortex of nude mice. The U87MG cell
line is derived from a patient diagnosed with glioblastoma
multiforme, a highly malignant and uniformly fatal brain tumor.
This tumor and other human glioblastomas and glioblastoma cell
lines contain a mutation in both PTEN alleles, resulting in a null
genotype. In light of these observations, we reconstituted the
PTEN gene in the parental U87MG (U87) cells.
Stable derivatives of the parental U87 cells were generated
after transduction with retroviruses encoding cDNA for WT
PTEN or specific mutants of this phosphatase. In particular, we
used missense mutations in the PTP signature motif to ascertain
the importance of the enzymatic activity of PTEN to its tumor
suppressor function. This included R130 M, in which all phos-
phatase activity is abrogated (5, 33), and G129E, which has been
identified in Cowden disease and endometrial cancer and in
which the activity toward inositol phospholipids is severely
attenuated but protein phosphatase activity is essentially intact.
Tumor cells were characterized biochemically for levels of
activated AKT (phospho-S473-AKT), growth in vitro, and PTEN
expression (Fig. 1). Anti-PTEN blots confirmed that parental
Fig. 1. Stable expression of PTEN and PTEN mutants in U87MG cells regulates
AKT. (A) Cell lysates from the U87MG (U87) cell line and U87 cells infected with
a retroviral vector encoding PTEN (pBabe-Puro-PTEN) or mutants of PTEN
(pBabe-Puro-PTEN-G129E or R130 M) were resolved by SDSyPAGE, and equal
amounts of proteins were loaded per lane, immunoblotted with antisera to
PTEN, phospho-AKT, and total AKT, and visualized by enhanced chemilumi-
nescence. The basal levels of PTEN (Top), phosphorylated AKT (Ser-473) (Mid-
dle), and total AKT (Bottom) are shown. The status of the PTEN gene in each
stable cell line was designated as: WT.E1 and WT.C7, two separate clones
expressing WT PTEN; R130 M and G129E are mutated PTEN, R130 M is inert as
both a protein and a lipid phosphatase. The G129E PTEN can dephosphorylate
acidic phosphopeptides, but cannot dephosphorylate lipid substrate,
PtdIns(3,4,5)P3. The U87MG (U87) cell line is the parental cell line isolated from
a human glioblastoma multiforme patient. (B) Comparison of in vitro growth
of U87MG cells transduced with mutants of PTEN. Equal number of cells (1 3
105) were incubated in RPMI 1 10% FBS for different times, and cell numbers
were quantitated by direct cell counting.











U87 cells do not express PTEN and that after reconstitution of
mutant or WT PTEN expression, U87 cells express amounts
comparable to WT physiological levels. Expression of WT
PTEN, to levels similar to those observed in a mouse brain lysate
and primary human astrocytes, suppressed the activated state of
AKT observed in PTEN-deficient U87 cells (Fig. 1 A, lanes 3 and
5). After expression of the R130 M and G129E mutant forms of
PTEN, the levels of phospho-AKT were similar to those ob-
served in the parental U87 cells (Fig. 1 A, lanes 1, 2, and 4),
suggesting that the lipid phosphatase activity of PTEN was
essential for the effects on the PtdIns(3,4,5)P3-dependent acti-
vation of AKT. Importantly, the growth of the different PTEN-
expressing U87 cell lines in vitro was similar in 2%, 5%, and 10%
FBS (data not shown and Fig. 1B). Therefore, we compared
these cell lines further in our in vivo models.
Effect of PTEN Reconstitution on in Vivo Growth and Proliferation. We
implanted athymic nude mice s.c. and by intracranial injection.
Production of s.c. tumors allowed us to monitor the size of the
tumor and perform direct biochemical analysis of tumor tissue
for PTEN expression and levels of AKT activation without
significant contamination from other tissues. Tumor tissue
blocks were processed for hematoxylinyeosin staining. Greater
than 95% of tissue analyzed was tumor. We compared the levels
of PTEN in tumor tissue and numerous normal tissues within the
athymic nude mouse. Using anti-PTEN antisera, we detected the
expression of PTEN in all tissues, with the exception of skeletal
and heart muscle (data not shown), but no PTEN was detected
in parental U87-derived tumor tissue (Fig. 2C, lane 4). These
results indicate that the tumor tissue sampled represents pre-
dominantly tumor cell-derived proteins. As observed in the cell
lines grown in vitro, s.c. tumors, derived from U87 cells recon-
stituted with mutant or WT PTEN, displayed similar levels of
PTEN expression (Fig. 2C, lanes 1–3 and 5). Phospho-AKT
activity was higher in PTEN-null U87 cells and U87 cells
reconstituted with R130 M and to a lesser extent in U87 cells
expressing the G129E mutant (Fig. 2C, lane 1) as compared with
the WT PTEN-transduced cells (Fig. 2C, compare lanes 1, 2, and
4 to lanes 3 and 5). The pattern of phosphorylated AKT was
similar when the different U87 mutant expressing cell lines were
assayed in vitro or in vivo (compare Fig. 1 A to 2C).
Despite the similar in vitro growth rate, there was a dramatic
difference in the growth of tumors derived from parental U87 cells
compared with cells reconstituted with WT PTEN (Fig. 2 A and B).
The average volume of U87-derived tumors on day 25 after
implantation was 848 6 203 mm3, compared with 91 6 27 mm3 for
tumors derived from WT PTEN-reconstituted cells (n 5 5, P ,
0.0001). Interestingly, the reconstitution of U87 cells with catalyt-
ically impaired PTEN (G129E or R130 M mutants) (Fig. 2A) shows
an intermediate level of growth suppression, a result that suggests
some residual function of these mutants in vivo.
Despite dramatic differences in the size of these tumors, in vivo
BrdUrd labeling of tumor cells revealed no significant difference
in number of cells in S phase: 72 6 6 BrdUrd-positive cells per
field in parental U87MG tumor mass versus 68.5 6 3 in WT
PTEN reconstituted tumors (data not shown). The percentage
of TUNEL-positive nuclei within the U87MG and WT PTEN
reconstituted tumors was similar. These results suggested that
something other than the proliferative or apoptotic rate of the
U87MG versus U87MG reconstituted with WT PTEN ac-
counted for the difference in growth potential. We observed that
the loss of inositol phospholipid phosphatase activity results in
deregulated tumor growth comparable to the total ablation of
catalytic activity and that the despite differences in overall
growth in vivo, the proliferative rate of these tumors is similar.
These findings are consistent with a role for PTEN in the
regulation of another aspect of tumor biology, such as angio-
genesis. This led us to assess the effect of PTEN reconstitution
on the induction of angiogenesis in this model.
PTEN Suppresses Tumor-Induced Angiogenesis. To examine the
effect of PTEN on angiogenesis, we compared parental U87 cells
to cells reconstituted with WT or mutant PTEN. We stained
cryostat sections from s.c. tumors for CD31 (PECAM). CD31 is
an endothelial marker used to measure the MVD of these
tumors. MVD was assessed from multiple digitized images of
CD31-stained tumor tissue at 3100 magnification (three fields
were evaluated per tumor) and counted blindly for the number
of CD31-positive microvessels per unit surface area as described
(32). Reconstitution of PTEN expression in U87 cells dramat-
ically suppressed the angiogenic response in vivo (Fig. 3 A and
B). Quantitation of MVD in tumors derived from parental U87
cells (77 6 13) and U87 cells expressing WT PTEN (38 6 7)
revealed an ’50% suppression of angiogenesis (Fig. 3C) (n 5 5,
P , 0.001). The MVD of tumors derived from U87 cells
reconstituted with catalytically impaired PTEN (R130 M, 84 6
15 or G129E, 69 6 16) were not significantly different (P . 0.05)
from the parental U87 cell line (Fig. 3C). The levels of phospho-
AKT detected within the tumor mass in vivo provide a correla-
tion between the loss of the inositol lipid phosphatase function
of PTEN, the phosphorylation status AKT, and the angiogenic
phenotype within the tumor.
PTEN Induction of Thrombospondin. Recent in vitro data suggest a
link between PTEN and downstream targets including AKT,
Fig. 2. Effects of PTEN on growth of U87MG cells in vivo. (A) Cell growth in vivo.
To determine the rate of cell growth in vivo, equal amounts of cells (5 3 106) from
each cell line were implanted at the right ventral flank by s.c. injection. The
formation and growth of the s.c. tumor was monitored, and the volume of the
tumor was determined by a three-dimensional measurement at the times indi-
cated (day0, thedateof implantation,notumor isdetected).Datawereanalyzed
byStudent’s t test,anddifferencesweresignificantcomparingthePTENdeficient
(U87MG, R130 M, G129E) to the WT PTEN (WT.E1, WT.C7), n 5 5, number of mice;
P , 0.0001. (B) Stereophotography of s.c. tumor sites in mice implanted with the
parental U87 tumor, PTEN minus (Left) versus WT PTEN reconstituted tumor cells
(Right). These tumors represent25and42daysafter implantationforPTENminus
versus WT PTEN reconstituted tumors, respectively. (Magnification, 340.) (C)
Immunoblot of cryostat tissue sections from s.c. tumor for the expression pattern
of PTEN, AKT, and phosphorylated AKT. Frozen tissue sections were solubilized in
Laemmli sample buffer, total protein was quantitated, and equal protein was
loaded on SDSyPAGE. The data shown are representative of tissue analysis from
five animals per experimental group.
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HIF1a, and vascular endothelial growth factor in the potential
control of angiogenesis (34, 35). We used the RNase protection
assay to confirm an observation we initially made during a cDNA
microarray analysis comparing the effect of PTEN reconstitu-
tion on U87MG TSP-1 expression. RNase protection assay was
performed with a TSP-1 specific probe in the same U87MG cells
constitutively expressing WT PTEN or G129R PTEN (Fig. 3D).
The data demonstrate that WT but not mutant PTEN expression
induces TSP-1 in U87 cells. To confirm these results, we per-
formed Western blot analysis for TSP-1 expression with a
retroviral-based ecdysone-inducible PTEN expression system
(36). Inducible and dose-dependent expression of PTEN was
confirmed in U87 cells, and we noted that the induced expression
of WT PTEN and not G129R PTEN (not shown) resulted in
augmented TSP-1 expression (Fig. 3E), and WT PTEN sup-
pressed the activation of phospho-AKT without affecting total
AKT (data not shown). The induced expression of mutant
G129R had no effect on phospho-AKT. Therefore, our data
demonstrate that PTEN positively modulates the expression of
TSP-1, a negative regulator of angiogenesis (Fig. 3 D and E) (37,
38). These data identify one potential mechanism by which
PTEN may regulate angiogenesis through the control of TSP-1.
PTEN Is a Determinant of Survival in Orthotopic Brain Tumor Model.
Brain tumor-induced angiogenic responses occur in the context
of brain-specific stromal and extracellular matrix interactions.
This fact led us to determine whether the expression of the
PTEN affects the survival of mice in an orthotopic brain tumor
model. For these experiments, U87 cells expressing either WT or
mutant forms of PTEN were implanted under stereotactic
control into the right frontal lobe of nude mice (Fig. 4B, see
arrow for site of implantation). The results indicate that recon-
stitution of WT PTEN in U87 cells suppressed the malignant
potential of these cells in an orthotopic animal model. Thus,
there was 90% survival at 40 days in animals implanted with the
WT PTEN-reconstituted U87 cells compared with 100% mor-
tality of mice implanted with the parental cells at 27 days (Fig.
4C) (n 5 15, P , 0.0001). PTEN reconstituted tumor cells grew
more slowly when implanted in the frontal lobe (Fig. 4, compare
A and B) and remained circumscribed to that area of brain (data
not shown). U87 cells reconstituted with mutants of PTEN,
either ablated in inositol lipid phosphatase activity (G129E) or
catalytically inactive (R130 M), displayed a phenotype similar to
the PTEN-negative, parental U87 cells (Fig. 4C). Animals with
tumors derived from U87 cells reconstituted with PTEN-G129E
displayed slightly prolonged survival (50% at day 30) compared
with those implanted with parental U87 cells; however, all
animals died by day 40. Immunohistochemical analysis for
CD31-positive neovascular structures within the brain tumor
demonstrated marked suppression of angiogenesis within the
brain tumor by WT PTEN reconstitution (compare CD31-
positive MVD in Fig. 4 D to F). These combined data suggest
that ablation of the inositol lipid phosphatase activity of PTEN
alone is sufficient to yield an angiogenic (Fig. 3) and malignant
glioma (Fig. 4C) after implantation of U87 tumor cells.
Discussion
In this report we have investigated the effects of expressing WT
and mutant forms of PTEN on the tumorigenicity of the U87
malignant glioblastoma cell line. We have observed that expres-
sion of WT PTEN did not affect the growth of the cell line in






Fig. 3. PTEN suppresses angiogenesis. Immunohistochemical analysis of staining with CD31 antibody to evaluate the angiogenesis response within the parental
U87MG tumor (A) and PTEN reconstituted tumors (B), implanted into the s.c. tissue. In PTEN minus and tumors expressing mutants of PTEN, there are more new
vessels formed (angiogenesis) (Upper, arrow indicated) than in WT PTEN reconstituted tumor (Lower), indicating the PTEN has direct influence on angiogenesis
during tumor growth. (C) MVD counts were performed on tumor tissue stained with anti-CD31 antibody as described (32) to determine the effect of expression
of PTEN and specific PTEN mutants (G129E or R130 M) on tumor-induced angiogenesis. Bars represent SD, five animals per group. Statistical analysis by Student’s
t test demonstrateed significant difference between MVD of PTEN null and PTEN catalytic mutants as compared with WT PTEN reconstituted tumors, n 5 5,
number of mice; P , 0.001. (D) PTEN regulates the expression of TSP-1 in U87MG cells. RNase protection assay was used to measure levels of TSP-1 mRNA in WT
PTEN expressing U87 cells or cells transduced with a mutant catalytically dead PTEN (G129R). U87MG cells were infected with retrovirus encoding WT PTEN (WT),
the catalytically dead, G129R mutant (GR), or empty vector retrovirus (2) and selected for 10 days in puromycin. RNA was harvested and RNase protection assays
were carried out by using probes for TSP-1 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH). A probe for GAPDH was used as a normalization control.
(E) Thrombospondin immunoblot analysis. U87MG transduced with WT PTEN (WT) or a catalytic mutant PTEN (G129R) in an ecdysone inducible expression system
(36) were induced (48 h) with 0.5 mM muristirone or assayed without induction to determine the effect of PTEN expression on the induction of TSP-1 by Western
blotting. Supernates from cells were prepared and proteins were resolved on SDSyPAGE and probed with anti-TSP-1 antibody. There is clear up-regulation of
TSP-1 in WT PTEN-transduced U87 cultures compared with U87 cells expressing the lipid phosphatase-deficient G129R mutant PTEN.











WT PTEN was indistinguishable from the parental U87MG line
when the cells were injected either s.c. or intracranially in nude
mice. Although the proliferative rates were indistinguishable,
there was a marked difference in tumor volume that was
accompanied by a dramatic difference in the vascularization of
the tumor. Even when tumors of the same size were assayed,
tumors derived from cells expressing WT PTEN had fewer blood
vessels than those derived from the parental cell line or cell lines
expressing mutant forms of PTEN. Importantly, use of a specific
point mutation in PTEN (PTEN G129E), in which lipid phos-
phatase activity is impaired but protein phosphatase activity
remains essentially intact (5), revealed that it is the lipid phos-
phatase activity of PTEN that is required for inhibition of
angiogenesis. Because the percentage of terminal deoxynucle-
otidyltransferase-mediated dUTP nick end labeling positive
nuclei within the U87MG and WT PTEN reconstituted tumors
was similar, the difference in tumor size is likely to be the result
of changes in PI3-kinase-dependent angiogenesis, rather than
effects on proliferative or apoptotic rates.
Other groups have noted that reconstitution of PTEN to
supraphysiological levels in the U87 cell line can suppress cell
proliferation (33, 39–44). In those experiments, PTEN was
noted to effect growth in vitro through the induction of a G1 cell
cycle arrest. We have been unable to detect a G1 arrest in our cell
lines. Significantly, our system was designed to express PTEN in
the U87 cells at levels similar to those observed in normal brain
or primary astrocytes. PTEN is catalytically active and may be
susceptible to regulation, for example, through interaction with
potential regulatoryytargeting proteins (45–49) or phosphory-
lation-dependent control at the level of proteolysis (50). There-
fore, we reasoned that even small deviations from physiological
levels could have profound repercussions on the maintenance of
the normal function and regulation of the phosphatase. It is
possible that the G1 arrest detected by many groups is a result of
the high levels of overexpression of PTEN. This conclusion is
supported by the finding that most cell lines and tissues express
PTEN without undergoing a G1 arrest.
As shown in our work, PTEN controls the expression and
secretion of TSP-1, a negative regulator of angiogenesis. The
work of Lawler et al. (51) and Hsu et al. (38) have clearly
established that TSP-1 exerts a negative control over endothelial
cell physiology and suppresses angiogenesis. A considerable
body of literature has established which domains of this complex
matrix protein exert its antiangiogenic effects and worked out
some of the mechanisms which underlie TSP-1 effects on
endothelial cells survival and angiogenesis (52, 53). Our data are
similar to the observation that p53 regulates angiogenesis and
provide evidence for one potential mechanism by which PTEN
may negatively regulate the angiogenic response by the induction
of TSP-1 expression. However, it seems unlikely that this is the
sole mechanism. Induction of TSP-1 expression by PTEN likely
reflects the recruitment of a larger program of gene expression,
one that is inhibitory to angiogenesis and tissue remodeling. Our
preliminary studies suggest that PTEN expression also induces
TIMP3, an inhibitor of matrix metalloproteinases, and sup-
presses matrix degradation in vivo, an important component of
angiogenesis in vivo. Further analysis of the role of PTEN in the
regulation of angiogenesis will increase our understanding
of how PtdIns(3,4,5)P3 pathways interface with the angiogenic
switch mechanisms.
PTEN was first characterized as a dual specificity phosphatase
that displayed selectivity for acidic substrates, including both
protein and nonprotein targets. Therefore, a question remains as
to which activity is essential to the tumor suppressor effects of
Fig. 4. Effects of PTEN reconstitution on survival in an orthotopic brain tumor model. Equivalent number of parental U87 cells or U87 cells reconstituted with
WT or mutant alleles of PTEN (1 3 106 cells) were implanted in right frontal lobe of nude mice. Stereophotography of whole brains from mice implanted with
U87MG tumor cells (day 25) (A) or PTEN reconstituted (day 42) (B). The implantation site is shown by position of arrow in the WT PTEN reconstituted tumor (B).
(Magnification: 320.) (C) Survival plots for mice implanted with PTEN minus or parental U87 cells transduced with mutants of PTEN as shown. Survival data
represents 15 animals per experimental group. P , 0.0001 for difference observed between the PTEN1 and PTEN2 groups for survival. (D) Immunohistochemical
analysis for anti-CD31 staining (brown staining) for microvessels within a U87MG parental PTEN-deficient brain tumor on day 22 after stereotactic implantation.
(E) Anti-CD31 staining of microvessels within a WT PTEN reconstituted U87MG brain tumor evaluated on day 42 after implantation. (F) MVD counts were
performed on brain tumor tissue stained with anti-CD31 antibody as described (32) to determine the effect of expression of PTEN and specific PTEN mutants
(G129E or R130 M) on tumor-induced angiogenesis. Bars represent SD, four animals per group. Statistical analysis by n 5 5 (number of mice), P , 0.01.
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PTEN. There have been suggestions that a primary target of
PTEN may be the protein tyrosine kinase, FAK, a regulator of
integrin-dependent signaling and cell migration (54). However,
the properties of U87 cells reconstituted with the PTEN-G129E
mutant suggest that it is the lipid phosphatase activity of PTEN
that is a critical determinant of its function in this brain tumor
model, in particular the induction of tumor-induced angiogenesis
in vivo. The observations of Holland et al. (55) are consistent
with this hypothesis: they reported that the introduction of
activated AKT, a downstream effector of PI3-kinase, into glial
cells of the mouse brain results in the development of glioblas-
tomas. Thus, our data and the data of Holland et al. suggest a
potential therapeutic benefit of inhibitors of PI3-kinase and
downstream targets such as AKT in treatment of malignant
gliomas. Preliminary work from our laboratory demonstrates
that the treatment of mice with the PI3-kinase inhibitor
LY294002 blocks angiogenesis and prevents the intracranial
growth of U87MG tumors (unpublished observation). Further
analysis should be directed at determining how LY294002
suppresses the angiogenic response of gliomas in this model.
Based on our combined data we suggest that PI3-kinase inhib-
itors may have efficacy in the treatment of malignant gliomas.
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